{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/immunizations-travel/management/japanese-encephalitis/","result":{"pageContext":{"chapter":{"id":"5c77503c-2f59-5696-908b-125fe0e8e41c","slug":"japanese-encephalitis","fullItemName":"Scenario: Japanese encephalitis","depth":2,"htmlHeader":"<!-- begin field bddccd1c-cd40-44b0-94b1-10744bb3c6c9 --><h2>Scenario: Japanese encephalitis</h2><!-- end field bddccd1c-cd40-44b0-94b1-10744bb3c6c9 -->","summary":"Covers advice for people travelling to areas endemic with Japanese encephalitis.","htmlStringContent":"<!-- begin item 67fb96e6-a362-41c9-adbd-343ed340f42c --><!-- begin field 4efdaa0b-dc7a-442e-b68b-acd900ab5243 --><p>From age 12 months onwards.</p><!-- end field 4efdaa0b-dc7a-442e-b68b-acd900ab5243 --><!-- end item 67fb96e6-a362-41c9-adbd-343ed340f42c -->","topic":{"id":"8f89ca7f-a4f5-5e7d-80c8-de5db64ca7f0","topicId":"16d61716-d647-48bc-827b-b2b115ecd0fb","topicName":"Immunizations - travel","slug":"immunizations-travel","lastRevised":"Last revised in January 2021","chapters":[{"id":"25b90177-7e96-59db-b325-abc5f51c8721","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bc7c22b0-dd64-50ad-8110-1fff4c8d6736","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"50f55046-7ca2-567f-94df-9c58f13770a5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2221cdd9-5576-5b5b-ad29-eff077930653","slug":"changes","fullItemName":"Changes"},{"id":"c755b06c-072d-5e60-be73-155dd664c37d","slug":"update","fullItemName":"Update"}]},{"id":"f5871d9a-dff3-59ce-a611-88d2ec41f5ce","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"513a86a0-e305-5e59-bd0d-1fb74a6e8689","slug":"goals","fullItemName":"Goals"},{"id":"87ea4699-bd41-5aeb-aa62-eac1fb591c4d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c8b054a0-ee87-5f9e-aa8f-c1fdf8442a29","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a8eb4582-f05d-5af5-ae78-497260724f93","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6f29b0b8-4b10-5e26-9ece-4cec050b1eb0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"79cb1d1a-ebd1-58c6-9bc5-2bfd006c22c1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8d3187f5-2a99-5108-a7c9-dd601d729381","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"055aad08-f5af-5b2f-bda0-a35213a2a071","slug":"travel-vaccinations","fullItemName":"Travel vaccinations"},{"id":"c8d1352b-616b-5dff-9517-ea235b83e9d9","slug":"diseases-commonly-requiring-vaccination","fullItemName":"Diseases commonly requiring vaccination"},{"id":"041fa115-033d-5525-91ce-c43dbf593bd4","slug":"other-diseases-requiring-vaccination","fullItemName":"Other diseases requiring vaccination"},{"id":"1fe14ee1-a79f-565a-9380-ae3be597d7d5","slug":"where-these-diseases-are-prevalent","fullItemName":"Where these diseases are prevalent"},{"id":"68e09f74-2282-532f-ae34-064998823fc1","slug":"payment-for-travel-vaccinations","fullItemName":"Payment for travel vaccinations"}]},{"id":"0e45089d-2317-5ec5-8c73-f0709c003c48","fullItemName":"Management","slug":"management","subChapters":[{"id":"9c16c0cb-4e78-523d-914f-e884aea62565","slug":"initial-assessment-advice","fullItemName":"Scenario: Initial assessment and advice"},{"id":"f911dc04-ffd0-5a41-a3cb-b724797a7589","slug":"cholera","fullItemName":"Scenario: Cholera"},{"id":"422ff6d3-5810-5d3c-93b3-c5a67faaa0e1","slug":"hepatitis-a","fullItemName":"Scenario: Hepatitis A"},{"id":"01d49a70-70f4-547a-a551-ab524f99c944","slug":"hepatitis-b","fullItemName":"Scenario: Hepatitis B"},{"id":"5c77503c-2f59-5696-908b-125fe0e8e41c","slug":"japanese-encephalitis","fullItemName":"Scenario: Japanese encephalitis"},{"id":"8cb4ca86-fe31-5603-a75e-84413c2b5346","slug":"meningococcal-meningitis","fullItemName":"Scenario: Meningococcal meningitis"},{"id":"0e84be27-375b-55f5-9f51-d0e4cc422b58","slug":"poliomyelitis","fullItemName":"Scenario: Poliomyelitis"},{"id":"37a96f8b-4158-5e62-8e3d-6cedae506976","slug":"rabies","fullItemName":"Scenario: Rabies"},{"id":"8c237a0e-a760-55b2-b7b0-5383b7653be3","slug":"tetanus","fullItemName":"Scenario: Tetanus"},{"id":"85c90e1f-26f4-503b-b0b0-7c5a38930086","slug":"tick-borne-encephalitis","fullItemName":"Scenario: Tick-borne encephalitis"},{"id":"4e817d26-15f3-5ff7-a672-11caa36ffb68","slug":"typhoid-fever","fullItemName":"Scenario: Typhoid fever"},{"id":"5ec20606-2af2-556b-98a6-d8673a21a09d","slug":"yellow-fever","fullItemName":"Scenario: Yellow fever"},{"id":"e0a021ac-7c76-551a-97af-25341142d54f","slug":"hajj-umrah-pilgrims","fullItemName":"Scenario: Hajj and Umrah pilgrims"},{"id":"087d9fbb-1ec6-5f08-8e76-5df3a4a0b863","slug":"rapid-vaccination-courses-vaccination-at-short-notice","fullItemName":"Scenario: Rapid vaccination courses and vaccination at short notice"}]},{"id":"79dee816-dbdb-5426-8db3-2f095eedbff3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f1e9d43f-6815-516a-8511-3fd34a06525d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a69fb594-d4b4-56e6-b46a-6283ead93e30","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"52eea726-d50b-5e4f-a22c-764c1961119d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b2033c1b-25a2-5a58-b99e-00baf9b02a96","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6df4842b-8812-534e-975d-52d29f3a8ee4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"81e42472-4b49-5390-8179-0d131f547700","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"86482706-09b2-5113-bd4e-261c392f6483","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0e45089d-2317-5ec5-8c73-f0709c003c48","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"b8c07763-51c3-5055-b4a1-10c9e0f46580","slug":"indications-for-vaccine","fullItemName":"Indications for vaccine","depth":3,"htmlHeader":"<!-- begin field 6d5f24b1-4157-4a61-b013-bbfe8d4da467 --><h3>Indications for vaccine</h3><!-- end field 6d5f24b1-4157-4a61-b013-bbfe8d4da467 -->","summary":null,"htmlStringContent":"<!-- begin item 4d9ab550-a87f-4dae-9732-0f74feb1e2f7 --><!-- begin field afb5432f-38cb-4cf3-918d-6a247261e398 --><ul><li><strong>Japanese encephalitis (JE) vaccination may be recommended for certain groups of people who are going to reside in an area where the disease is endemic or epidemic, such as:</strong><ul><li>Travellers to South-East Asia and the Far East staying for a month or longer in endemic areas during the transmission season, especially if travel will include rural areas.</li><li>Travellers with exposure periods of less than 1 month who will be spending time in rice fields (where the mosquito vector breeds) or close to pig farming (a reservoir host for the virus).</li></ul></li><li>Country-specific recommendations and information on the global epidemiology of JE can be found on the <a href=\"http://travelhealthpro.org.uk/\" data-hyperlink-id=\"69e785a6-67df-46c3-81bc-a931009ecfa5\">TravelHealthPro</a> website.</li><li>Note: travellers to endemic regions are also advised to use standard precautions to prevent mosquito bites, as JE is transmitted to humans by <em>Culex </em>mosquitoes.</li></ul><!-- end field afb5432f-38cb-4cf3-918d-6a247261e398 --><!-- end item 4d9ab550-a87f-4dae-9732-0f74feb1e2f7 -->","subChapters":[{"id":"c9d9b171-be29-5ff7-9bbb-cd1e926a6569","slug":"basis-for-recommendation-117","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8df9d860-5bb0-4a75-946e-9abe152c3253 --><h4>Basis for recommendation</h4><!-- end field 8df9d860-5bb0-4a75-946e-9abe152c3253 -->","summary":null,"htmlStringContent":"<!-- begin item 11795294-c0a9-4cc7-afe1-e2696849aeaa --><!-- begin field 3f26d804-eabf-4dca-adff-bab07c93d01c --><p>The recommendations on indications for Japanese encephalitis vaccination are based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 20: Japanese Encephalitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2018a</a>].</p><!-- end field 3f26d804-eabf-4dca-adff-bab07c93d01c --><!-- end item 11795294-c0a9-4cc7-afe1-e2696849aeaa -->","subChapters":[]}]},{"id":"917435f0-8047-56dc-89ac-8af03eefe209","slug":"available-vaccines-vaccination-schedules","fullItemName":"Available vaccines and vaccination schedules","depth":3,"htmlHeader":"<!-- begin field 298e6ae6-2d27-4e7f-8b18-9daf8cfb5730 --><h3>Available vaccines and vaccination schedules</h3><!-- end field 298e6ae6-2d27-4e7f-8b18-9daf8cfb5730 -->","summary":null,"htmlStringContent":"<!-- begin item 0fbbb4c1-0c78-4089-8428-34f26e5336d7 --><!-- begin field d127f8b6-8630-4dbd-8cdb-93d999a8a354 --><ul><li><strong>One inactivated Japanese encephalitis vaccine (IXIARO<sup>®</sup>)<sup> </sup>is<sup> </sup>currently licensed in the UK for use in infants from 2 months of age, children, and adults.</strong></li><li>There are two routine schedules for IXIARO<sup>® </sup>vaccine depending on the age of the person (see Table 4).</li><li>Ideally, the vaccination schedule should be completed 1 week before travel to allow immunity to develop.</li></ul><p><strong>Table 4</strong><strong>. </strong>Recommended schedule for Japanese encephalitis IXIARO<sup>® </sup>vaccine.</p><table data-table-id=\"a47bef80-69e4-4fc8-a239-acce014c6dc1\"><thead><tr><th><p>Age range</p></th><th><p>Schedule</p></th><th><p>Booster doses</p></th></tr></thead><tbody><tr><td>Children aged 2 months to under 36 months</td><td>2 doses of 0.25 mL: Day 0 and 28<sup>*</sup>.</td><td>Boost at 12–24 months following primary course, if at continued risk of infection.</td></tr><tr><td>Children and young people aged 3 years and over and adults</td><td>2 doses of 0.5 mL: Day 0 and 28<sup>*</sup>.</td><td><p>For all age groups, offer a first booster at 12–24 months following primary course, if at continued risk of infection.</p><p>For adults aged 18–64 years of age, a second booster should be offered at 10 years to those who remain at risk.</p><p>For other age groups, there are no serology data on which to base any recommendations about timing of a second booster dose.</p></td></tr><tr><td colspan=\"3\"><p><sup>*</sup>A rapid schedule of IXIARO<sup>® </sup>administered at days 0 and 7 is also licensed for adults aged 18–64 years of age. Antibody responses are non-inferior to those of the standard vaccination schedule. The rapid schedule may be used in children from 2 months to 17 years of age and adults 65 years of age and older (off-licence use) where there is insufficient time to complete the standard schedule before travel.</p></td></tr></tbody></table><p> </p><!-- end field d127f8b6-8630-4dbd-8cdb-93d999a8a354 --><!-- end item 0fbbb4c1-0c78-4089-8428-34f26e5336d7 -->","subChapters":[{"id":"29dc377e-fb87-5230-8fca-22f0279d6e2d","slug":"basis-for-recommendation-b9b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9b4835f1-dae5-456e-827b-4f7a41f0f8f3 --><h4>Basis for recommendation</h4><!-- end field 9b4835f1-dae5-456e-827b-4f7a41f0f8f3 -->","summary":null,"htmlStringContent":"<!-- begin item b9b64931-cc0a-441d-84fa-b05dc4d8c422 --><!-- begin field 982b7dee-1018-4c10-829e-cfe1d17b9bd1 --><p>The information on available types of Japanese encephalitis vaccine and vaccination schedules is based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book)</em> <em>Chapter 20: Japanese encephalitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2018a</a>].</p><!-- end field 982b7dee-1018-4c10-829e-cfe1d17b9bd1 --><!-- end item b9b64931-cc0a-441d-84fa-b05dc4d8c422 -->","subChapters":[]}]},{"id":"d70abacb-1507-5aa4-93be-604700012dfb","slug":"contraindications-to-vaccine","fullItemName":"Contraindications to vaccine","depth":3,"htmlHeader":"<!-- begin field 58e9fcc0-79b8-4f5b-bead-c8d3212d16c0 --><h3>Contraindications to vaccine</h3><!-- end field 58e9fcc0-79b8-4f5b-bead-c8d3212d16c0 -->","summary":null,"htmlStringContent":"<!-- begin item 61dcba53-a04b-4025-815a-7a3b68243564 --><!-- begin field 57b22fc3-640d-4548-9b11-25d13c1a6c36 --><ul><li><strong>Japanese encephalitis vaccine should not be given to people who have had:</strong><ul><li>A confirmed anaphylactic reaction, or serious systemic reaction (e.g. generalized urticaria or angio-oedema) following a previous dose.</li><li>A confirmed anaphylactic reaction to any component of the vaccine.</li></ul></li><li><strong>Japanese encephalitis vaccine should be avoided in pregnancy where possible, due to a theoretical risk of fetal infection from live vaccines. </strong>However, healthcare professionals should help pregnant women to make an informed choice about use of the vaccine by discussing with them the theoretical risks of vaccine exposure versus the potential risk of acquiring Japanese encephalitis.</li></ul><!-- end field 57b22fc3-640d-4548-9b11-25d13c1a6c36 --><!-- end item 61dcba53-a04b-4025-815a-7a3b68243564 -->","subChapters":[{"id":"144917bd-269a-5ad4-bb23-6157f4d1ae1e","slug":"basis-for-recommendation-b73","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 42693509-8bfc-4dbb-b8b5-cc4f6c5004df --><h4>Basis for recommendation</h4><!-- end field 42693509-8bfc-4dbb-b8b5-cc4f6c5004df -->","summary":null,"htmlStringContent":"<!-- begin item b73e6503-c96b-4435-8d61-6b543f788e35 --><!-- begin field f1a42997-ff5c-4716-8e1b-d3ba1cf52444 --><p>The information on contraindications to Japanese encephalitis vaccination is based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 20: Japanese encephalitis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2018a</a>] and <em>Chapter 6: Contraindications and special considerations</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2017a</a>].</p><!-- end field f1a42997-ff5c-4716-8e1b-d3ba1cf52444 --><!-- end item b73e6503-c96b-4435-8d61-6b543f788e35 -->","subChapters":[]}]},{"id":"48e58d25-d7e8-54fd-8685-edb65638844b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 43ca2c49-7a10-4a88-a6f8-ff90cb8f7d2b --><h3>Adverse effects</h3><!-- end field 43ca2c49-7a10-4a88-a6f8-ff90cb8f7d2b -->","summary":null,"htmlStringContent":"<!-- begin item 919d048e-5bfe-40f0-b222-3a9b32899a12 --><!-- begin field 5f04f333-f82a-4a65-ba39-3e39cc4f97c0 --><ul><li>The most common adverse reactions observed after administration of IXIARO<sup>®</sup> are pain and tenderness at the injection site, headache, and myalgia.</li><li>Other reactions commonly reported are erythema, hardening, swelling, and itching at the injection site, influenza-like illness, pyrexia, and fatigue.</li></ul><!-- end field 5f04f333-f82a-4a65-ba39-3e39cc4f97c0 --><!-- end item 919d048e-5bfe-40f0-b222-3a9b32899a12 -->","subChapters":[{"id":"245bc37b-2b75-5a01-bfc6-ddad6ae25d0e","slug":"basis-for-recommendation-9fc","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3a9fe879-40fb-48be-a9af-260c66826637 --><h4>Basis for recommendation</h4><!-- end field 3a9fe879-40fb-48be-a9af-260c66826637 -->","summary":null,"htmlStringContent":"<!-- begin item 9fcf228c-d526-414a-9a6a-e9bafdc2c3dc --><!-- begin field f162f29a-dd90-462e-8a28-e4df7170fe70 --><p>The information on adverse effects of Japanese encephalitis vaccination is based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 20: Japanese encephalitis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2018a</a>].</p><!-- end field f162f29a-dd90-462e-8a28-e4df7170fe70 --><!-- end item 9fcf228c-d526-414a-9a6a-e9bafdc2c3dc -->","subChapters":[]}]},{"id":"05eacd39-759f-5c54-8964-6f4fef6c81e7","slug":"how-to-administer-the-japanese-encephalitis-vaccine","fullItemName":"How to administer the Japanese encephalitis vaccine","depth":3,"htmlHeader":"<!-- begin field 31f92e0a-813f-45c7-b7e5-d56d07394a45 --><h3>How to administer the Japanese encephalitis vaccine</h3><!-- end field 31f92e0a-813f-45c7-b7e5-d56d07394a45 -->","summary":null,"htmlStringContent":"<!-- begin item 3c01c8df-123d-47a4-933a-9b7f3d8a3f45 --><!-- begin field 29de2bcf-92aa-4576-b725-2b89fbe3c375 --><ul><li><strong>Obtain written or verbal consent at the time of vaccination for people aged over 16 years.</strong><strong> For younger people it is usual to get consent from a person with parental responsibility.</strong><ul><li>Adults over 18 years of age are presumed to be competent to consent to treatment provided they can comprehend and retain the information they are given, and they can consider the facts and make an informed decision.</li></ul></li><li><strong>Ensure that:</strong> <ul><li>There are no <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-travel/management/japanese-encephalitis/#contraindications-to-vaccine\">Contraindications to the vaccine</a>.</li><li>The person, parent, or carer has been fully informed about the vaccine and the vaccination procedure.</li><li>Possible <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-travel/management/japanese-encephalitis/#adverse-effects\">adverse reactions</a> have been discussed and the person, parent, or carer is aware of how to manage them. </li><li>The vaccine is correct, has been stored appropriately, and has not expired. </li></ul><ul><li>The vaccination site has been washed with soap and water if it is visibly dirty. </li></ul></li><li><strong>Japanese encephalitis vaccine is usually given by intramuscular (IM) injection,</strong> into the upper arm in children and adults, or the anterolateral thigh in infants under 1 year of age. However, if the person has a bleeding disorder, the vaccine should be given by deep subcutaneous (SC) injection to reduce the risk of bleeding. </li><li><strong>Japanese encephalitis vaccine can be given at the same time as other vaccines.</strong> If an additional vaccine is required on the same day, use separate limbs if possible, or inject at sites at least 2.5 cm apart. </li><li><strong>Record the date of administration, vaccine and product name, batch number, expiry date, dose administered, and site of administration for each vaccine.</strong> </li><li><strong>Observe the person after vaccination to detect immediate adverse reactions.</strong> Ensure any bleeding has stopped and check for any symptoms of anaphylaxis before they leave.<ul><li>Anaphylaxis is extremely rare, and usually becomes apparent within minutes. By the time the site has been checked for bleeding and documentation has been completed, most reactions will have become apparent. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul></li></ul><!-- end field 29de2bcf-92aa-4576-b725-2b89fbe3c375 --><!-- end item 3c01c8df-123d-47a4-933a-9b7f3d8a3f45 -->","subChapters":[{"id":"5ede235b-0188-5c5e-a64f-101a812f4133","slug":"basis-for-recommendation-dec","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6a9fe4e1-0243-4fe5-b733-6eb70e4e4f1d --><h4>Basis for recommendation</h4><!-- end field 6a9fe4e1-0243-4fe5-b733-6eb70e4e4f1d -->","summary":null,"htmlStringContent":"<!-- begin item decc443f-1462-4fd8-aeea-95c1788af8c3 --><!-- begin field 8bb5b258-c4eb-4a2e-8462-818fcf4d0a69 --><p>The recommendations on how to administer the Japanese encephalitis vaccine are based on expert opinion in the Department of Health publication <em>Immunisation against infectious disease (The Green Book) Chapter 20: Japanese encephalitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2018a</a>], <em>Chapter 2: Consent</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013e</a>], <em>Chapter 4: Immunisation procedures</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013f</a>], and <em>Chapter 8: Vaccine safety and adverse effects</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013g</a>], and are also pragmatic, based on what CKS considers to be good clinical practice.</p><h5>Obtaining consent</h5><ul><li>Consent for immunizations does not legally have to be in writing, but must be given voluntarily by a fully informed person who is able to make and communicate their decision. For children not competent to give or withhold consent, a person with parental responsibility can provide this [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013e</a>].</li></ul><h5>Site of administration</h5><div><ul><li>In people over the age of 1 year, vaccines are routinely given into the deltoid muscle as it is convenient, providing easy access, and it reduces the risk of localized reactions, which are common when vaccines are given subcutaneously.</li><li>The gluteal muscle should be avoided. The needle may not penetrate through adipose tissue into the muscle, and this may cause a poor immunological response to the vaccine. In addition, there is a risk of damage to underlying structures such as the sciatic nerve [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-travel/references/\">PHE, 2013f</a>].</li></ul></div><!-- end field 8bb5b258-c4eb-4a2e-8462-818fcf4d0a69 --><!-- end item decc443f-1462-4fd8-aeea-95c1788af8c3 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}